256940.KQ KPS Corporation
- Market cap
- KRW 102B
- P/E
- -
- P/B
- 1.64x
- ROE
- -9.9%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 256940.KQ undervalued?
Graham numberThe Graham number of KPS Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KPS Corporation fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-9.9%), below 10%.
ROA 0/1
Return on assets (-2.6%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-920.6%) is below the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 126.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (58.9%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.6x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
KPS Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KPS Corporation
Keeps Biopharma Inc. engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. It offers OLED equipment, inspection technologies, camera modules, precision systems, and TSP/solar products. The company is also involved in bio research and development business; waste battery recycling; and other non-ferrous metal smelting, refining, and alloy manufacturing. The company wa…
Full company profileKPS Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KPS Corporation annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.5B | 24.0B | 40.6B | 14.2B | 15.2B | 4.26B | 14.6B | 92.1B | 128B | 170B | 269B |
| Gross Profit | 6.11B | 9.24B | 14.0B | 3.58B | 3.95B | -789M | 1.04B | 12.8B | 17.2B | 37.6B | 38.2B |
| Operating Income | 2.72B | 4.26B | 7.61B | -973M | -387M | -12.3B | -7.76B | 11.2B | 6.22B | 1.57B | -6.12B |
| EBITDA | - | - | - | - | - | - | -11.9B | 8.84B | 9.68B | -49.7M | -6.12B |
| Net Income | 2.56B | 2.19B | 6.81B | -346M | -2.41B | -15.3B | -11.4B | 3.93B | 1.11B | -9.79B | -6.19B |
| EPS | 291 | 171 | 530 | -27 | -157 | -826 | -607 | 210 | 59 | -487 | -308 |
| Balance Sheet | |||||||||||
| Total Assets | 27.1B | 32.5B | 38.2B | 38.7B | 77.0B | 93.4B | 85.6B | 117B | 165B | 234B | 234B |
| Total Liabilities | 20.8B | 6.75B | 7.32B | 8.35B | 26.8B | 32.4B | 32.5B | 58.7B | 102B | 152B | 154B |
| Shareholders' Equity | 6.25B | 25.7B | 30.9B | 30.3B | 50.2B | 61.0B | 53.1B | 57.2B | 50.1B | 62.0B | 62.6B |
| Cash & Short-term Investments | 3.02B | 12.5B | 8.23B | 12.1B | 31.7B | 40.9B | 30.5B | 14.6B | 24.4B | 22.0B | 11.5B |
| Total Debt | 10.0B | 1.53B | 460M | 74.6M | 4.68B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.58B | 6.48B | 2.37B | -731M | -1.74B | -8.38B | -866M | -57.1M | 4.81B | -14.9B | -8.79B |
| Capital Expenditure | 1.13B | 618M | 5.30B | 23.9M | 1.04B | 90.8M | 95.9M | 1.07B | 6.70B | 34.9B | 8.67B |
| Free Cash Flow | - | - | - | - | -3.43B | -8.50B | -996M | -1.13B | -1.89B | -49.8B | -17.5B |
| Ratios | |||||||||||
| ROE | 40.9% | 8.5% | 22.0% | -1.1% | -4.8% | -25.1% | -21.4% | 6.9% | 2.2% | -15.8% | -9.9% |
| ROA | 9.4% | 6.7% | 17.8% | -0.9% | -3.1% | -16.4% | -13.3% | 3.4% | 0.7% | -4.2% | -2.6% |
| Net Profit Margin | 14.6% | 9.1% | 16.8% | -2.4% | -15.8% | -359.5% | -77.8% | 4.3% | 0.9% | -5.8% | -2.3% |
| Debt to Equity | 1.60x | 0.06x | 0.01x | 0.00x | 0.09x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
KPS Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | KRW 428M | 33 | - |
| 2018 | KRW 428M | 33 | 6.3% |
| 2017 | KRW 428M | 33 | 19.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on May 20, 2020.
Who owns KPS Corporation
- Insiders 22.82%
- Institutions 0.61%
- Public & others 76.58%
- Shares outstanding 20.1M
- Free float 14.7M
KPS Corporation company profile
- Company name
- KPS Corporation
- Ticker
- 256940.KQ
- ISIN
- KR7256940008
- Exchange
- KOSDAQ
- Sector
- Consumer Defensive
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 128
- Fiscal year end
- December
- Address
- 52, Dongtansandan 10-gil, Hwaseong-si, South Korea, 18487
- Phone
- 82 31 8041 5400
- Website
- kpscorp.co.kr/kps/index.php
About KPS Corporation
Keeps Biopharma Inc. engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. It offers OLED equipment, inspection technologies, camera modules, precision systems, and TSP/solar products. The company is also involved in bio research and development business; waste battery recycling; and other non-ferrous metal smelting, refining, and alloy manufacturing. The company was formerly known as KPS Corporation and changed its name to Keeps Biopharma Inc. in April 2025. Keeps Biopharma Inc. was founded in 2000 and is headquartered in Hwaseong-si, South Korea.
KPS Corporation management
2- Young Kim HaChief Executive Officer
- Jung Ho KimCEO of KPS Technology Division